593 related articles for article (PubMed ID: 31991110)
21. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
23. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
24. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
25. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
26. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.
Sakai R; Kagawa S; Yamasaki Y; Kojima T; Uno F; Hashimoto Y; Watanabe Y; Urata Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2010 Jun; 9(6):1884-93. PubMed ID: 20501801
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
30. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].
Hashimoto M; Kuroda S; Kanaya N; Kakiuchi Y; Kikuchi S; Tazawa H; Kagawa S; Urata Y; Fujiwara T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1127-1129. PubMed ID: 36281608
[TBL] [Abstract][Full Text] [Related]
31. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
32. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
[TBL] [Abstract][Full Text] [Related]
33. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
Fujiwara T; Kagawa S; Tazawa H
Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
[TBL] [Abstract][Full Text] [Related]
34. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
35. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
36. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
[TBL] [Abstract][Full Text] [Related]
38. Modification of oncolytic adenovirus and its application in cancer therapy.
Liang Y; He J; Zhao Y
Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481
[TBL] [Abstract][Full Text] [Related]
39. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
